Type 1 diabetes, devices and technology

Closed-loop control with the Cambridge hybrid system improves time in range in very young children with type 1 diabetes relative to sensor-augmented pump delivery over 16 weeks of use, researchers report.

The newly published ADA/EASD consensus report on the management of type 1 diabetes provides a comprehensive overview of the care required to help people with the condition live a full and healthy life.

Click through to read more on this announcement

The Cambridge closed-loop insulin delivery system significantly improves glycemic control during 6 months of use by children and adolescents compared with standard insulin pump therapy, report the DAN05 investigators.

Use of the Omnipod 5 closed-loop insulin delivery system reduces diabetes distress and improves quality of life, particularly for the carers of children with type 1 diabetes, research shows.

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

Use of continuous glucose monitoring within the first month of diagnosis is associated with an improvement in glycemic control among youth with type 1 diabetes, indicate findings from the 4T study.

Gaining greater control of blood glucose and hypoglycemia awareness is associated with a reduction in diabetes distress among people who start using the FreeStyle Libre, researchers report.

A closed-loop system with an artificial intelligence component that rapidly detects when the user is eating a meal may offer a route towards fully closed-loop insulin delivery, shows a small crossover trial in adolescents and young adults.

A consensus statement covering the practical, ethical, and legal aspects of the use of open-source closed-loop insulin delivery algorithms is soon to be published, the authors reported at the virtual ATTD 2021 conference.

Completing a brief, adaptive questionnaire prior to each consultation with healthcare providers can focus discussions toward the immediate priorities and concerns of people with diabetes, shows a feasibility study.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Switching from intermittently scanned to real-time continuous glucose monitoring improves time in range by a clinically relevant percentage, show the findings of the 6-month ALERTT1 trial.

Use of an insulin pump is not associated with better glycemic control than multiple daily injections among children and adolescents with type 1 diabetes, indicate real-world study results.

People with impaired hypoglycemia awareness become more proactive about treating low blood glucose when they start using continuous glucose monitoring, but do not adjust their insulin usage, show data from HypoDE.

A large real-world study shows improved glycemic outcomes for adults and children who initiate use of the Loop DIY automated insulin delivery system using community resources.

People with type 1 diabetes who are “hyperglycemia aversive” reduce their hyperglycemia exposure at the cost of increased hypoglycemia and, potentially, reduced hypoglycemia awareness, research suggests.

Flash glucose monitoring is associated with small but sustained improvements in glycemic control and a reduction in severe hypoglycemia relative to self-monitoring of blood glucose in type 1 diabetes, observational data show.

The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.

Among people with type 1 diabetes, adding the SGLT2 inhibitor empagliflozin to an automated insulin delivery system may allow replacement of carbohydrate counting with a simple meal announcement, suggest findings from a pilot randomized trial.